Advanced Breast Cancer: Expert Perspectives On Recent Progress

EP. 1: Perspectives on Recent Progress: Program Overview

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology

July 14th 2020

EP. 2: Phase 3 KEYNOTE-355 Overview

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology

July 14th 2020

EP. 3: PD-L1 Testing Standard of Practice

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology

July 14th 2020

EP. 4: KEYNOTE-355 Regimen’s Role in Treatment Paradigm

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology

July 14th 2020

EP. 5: ASCO New Data: PARP Inhibitors

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology

July 14th 2020

EP. 6: SWOG S1416 and TBCRC 048 Phase 2 Trial Overviews

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology

July 14th 2020

EP. 7: Phase 3 ASCENT Regimen Accelerated Approval

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology

July 14th 2020

EP. 8: Next-Generation Sequencing: Triple Negative Breast Cancer

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology

July 14th 2020

EP. 9: CDK4/6 Inhibition in HR+ Metastatic Breast Cancer

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology

July 14th 2020

EP. 10: CDK4/6 Clinical Trial Survival Data Impact

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology

July 14th 2020

EP. 11: CDK4/6 Meta-Analysis Data

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology

July 14th 2020

EP. 12: Mechanisms of Resistance to CDK4/6 Inhibitors

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology

July 14th 2020

EP. 13: Significance of PIK3CA Mutation in HR+ Breast Cancer

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology

July 14th 2020

EP. 14: After Progression on PIK3CAi Therapy: MTOR Inhibition

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology

July 14th 2020

EP. 15: HER2+ MBC Adverse-Event Management

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology

July 14th 2020

EP. 16: Notable ASCO Trial Updates

ByJoyce A. O'Shaughnessy, MD, Baylor Charles A. Sammons Cancer Center,Dejan Juric, MD, Massachusetts General Hospital,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Denise Yardley, MD, Tennessee Oncology

July 14th 2020

Episodes

EP. 1: Perspectives on Recent Progress: Program Overview

EP. 2: Phase 3 KEYNOTE-355 Overview

EP. 3: PD-L1 Testing Standard of Practice

EP. 4: KEYNOTE-355 Regimen’s Role in Treatment Paradigm

EP. 5: ASCO New Data: PARP Inhibitors

EP. 6: SWOG S1416 and TBCRC 048 Phase 2 Trial Overviews

EP. 7: Phase 3 ASCENT Regimen Accelerated Approval

EP. 8: Next-Generation Sequencing: Triple Negative Breast Cancer

EP. 9: CDK4/6 Inhibition in HR+ Metastatic Breast Cancer

EP. 10: CDK4/6 Clinical Trial Survival Data Impact

EP. 11: CDK4/6 Meta-Analysis Data

EP. 12: Mechanisms of Resistance to CDK4/6 Inhibitors

EP. 13: Significance of PIK3CA Mutation in HR+ Breast Cancer

EP. 14: After Progression on PIK3CAi Therapy: MTOR Inhibition

EP. 15: HER2+ MBC Adverse-Event Management

EP. 16: Notable ASCO Trial Updates

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC

Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL

Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments